+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "GLP-1 Receptor Agonist"

From
Asia-Pacific Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

Asia-Pacific Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 97 Pages
  • Asia Pacific
From
North America Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

North America Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 89 Pages
  • North America
From
Diabetes Drug Market Overview, 2025-30 - Product Thumbnail Image

Diabetes Drug Market Overview, 2025-30

  • Report
  • June 2025
  • 109 Pages
  • Global
From
South America Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

South America Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 81 Pages
From
Europe Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

Europe Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 100 Pages
  • Europe
From
Middle East and Africa Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

Middle East and Africa Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 81 Pages
  • Middle East, Africa
From
Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 198 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
United Arab Emirates Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update - Product Thumbnail Image

United Arab Emirates Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update

  • Report
  • March 2025
  • 50 Pages
  • United Arab Emirates United Arab Emirates
From
From
From
Loading Indicator

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite. GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance. Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more